Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2013
09/19/2013WO2013137441A1 Oral pharmaceutical composition
09/19/2013WO2013137433A1 Novel antitumor agent comprising combination of three agents
09/19/2013WO2013137427A1 Novel pyrimidine nucleoside compound
09/19/2013WO2013137382A1 Bone metabolism improving agent
09/19/2013WO2013137371A1 Novel pyrimidine compound and medicine comprising same
09/19/2013WO2013137328A1 Method for screening anticancer drugs, and anticancer drug that induces cell death and uses substance that increases granzyme m activity as active ingredient
09/19/2013WO2013137284A1 Sulfur amino acid-containing composition
09/19/2013WO2013137009A1 Ameliorating agent for chronic obstructive pulmonary disease
09/19/2013WO2013136871A1 Oversulfated chondroitin composition
09/19/2013WO2013136770A1 Ultraviolet absorber
09/19/2013WO2013136277A1 Pharmaceutical compositions for treatment of cardiovascular diseases
09/19/2013WO2013136070A1 A sik inhibitor for use in a method of treating an inflammatory and/or immune disorder
09/19/2013WO2013136061A1 New polymorphic form of a long-acting beta-2 adrenoceptor agonist
09/19/2013WO2013136040A1 Polypeptides and their use
09/19/2013WO2013135930A1 Compounds derived from doxycycline such as haptens, conjugates and antibodies thereof, and immunochemical method for detecting doxycycline
09/19/2013WO2013135884A1 Paralytic shellfish poison
09/19/2013WO2013135881A1 Process for preparing sterile brinzolamide
09/19/2013WO2013135880A1 Combination of a mc1r receptor agonist and uvb for the treatment and/or prevention of pigmentation disorders
09/19/2013WO2013135853A1 Pharmaceutical packaging product for the veterinary medical sector
09/19/2013WO2013135852A1 Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
09/19/2013WO2013135803A1 Thiophene-based compounds exhibiting nox4 inhibitory activity and use thereof in therapy
09/19/2013WO2013135789A1 Means and methods for the determination of the joint destruction progression rate in rheumatoid arthritis patients
09/19/2013WO2013135766A1 Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia
09/19/2013WO2013135750A1 A new class of diazepine derivative chelating agents and complexes with paramagnetic metals thereof as mri contrast agents
09/19/2013WO2013135745A1 Methods of treating melanoma with pak1 inhibitors
09/19/2013WO2013135727A1 Glioma treatment by convection enhanced delivery
09/19/2013WO2013135648A1 Substituted pyrrolidine-2-carboxamides
09/19/2013WO2013135647A1 Composition for use in preventing or reducing postoperative adhesions
09/19/2013WO2013135612A1 Substituted imidazopyridazines
09/19/2013WO2013135596A1 Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis
09/19/2013WO2013135571A1 Compositions with enhanced therapeutic efficacy against infective agents of the eye comprising miltefosine and polyhexamethylene biguanide
09/19/2013WO2013135192A1 Novel use of patchoulol
09/19/2013WO2013135189A1 Solid dispersion improving absorption performance and preparation of same
09/19/2013WO2013135187A1 Solid dispersion of improved adsorption performance and preparation thereof
09/19/2013WO2013135176A1 Aminoquinazoline derivative and use thereof in preparing anti-malignant tumor medicament
09/19/2013WO2013135147A1 Use of substituted diphenylamine compounds in preparing anti-tumour drugs
09/19/2013WO2013134869A1 Novel sulfonate-based trimebutine salts
09/19/2013WO2013134867A1 Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
09/19/2013WO2013113030A3 Fads regulation
09/19/2013WO2013112949A3 Treatment of circadian rhythm disorders
09/19/2013WO2013112762A4 Bendamustine compositions and methods therefore
09/19/2013WO2013104892A8 Application of high dose compounds via inhalation
09/19/2013WO2013103836A3 Methods of treating cancer
09/19/2013WO2013102929A4 Novel compounds for treatment of diabetes, obesity or related disorders
09/19/2013WO2013102878A3 Fat1 gene in cancer and inflammation
09/19/2013WO2013102843A3 Dualistic molecules having uv radiation filtrating ability at wide spectrum and potent damping activity of the reactivity of free radicals (radicals scavenging)
09/19/2013WO2013100821A3 Agent for treating diabetes
09/19/2013WO2013086243A3 Phospholipid compositions enriched for palmitoleic, myristoleic or lauroleic acid, their preparation and their use in treating metabolic and cardiovascular disease
09/19/2013WO2013084216A3 Heteroaryl compounds and uses thereof
09/19/2013WO2013080217A4 Crystalline forms of carbazitaxel and process for preparation thereof
09/19/2013WO2013061105A8 Glycogen phosphorylase inhibitors
09/19/2013WO2013051904A3 Composition for preventing and treating vision deterioration and age-related macular degeneration through retinal repair using ginseng/red ginseng extracts and ginsenoside
09/19/2013WO2013046194A3 The novel reference markers for fesoterodine fumarate
09/19/2013WO2013028818A8 Pyrimido- pyridazinone compounds and use thereof
09/19/2013WO2013003601A9 Method for treating phytophotodermatitis
09/19/2013WO2012177925A8 Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
09/19/2013WO2012135970A8 Inhibitors of phosphatidic acid phosphohydrolase (pap), including d-propranolol and analogs thereof, alone or in combination with desipramine, for the treatment of cancers that depend on the epidermal growth factor receptor (egfr), oncogenic variants thereof and other members of the erbb/her family
09/19/2013WO2012123952A8 Enantiomers of fluconazole analogues containing thieno-[2,3-d]pyrimidin-4(3h)-one moiety as antifungal agents
09/19/2013WO2012117257A8 Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
09/19/2013WO2012107706A8 Phenothiazine diaminium salts and their use
09/19/2013WO2012087115A8 Cancer targeting using carbonic anhydrase isoform ix inhibitors
09/19/2013WO2012074862A3 Processes for the preparation of enamines
09/19/2013US20130245618 Controlled laser treatment for non-invasive tissue alteration, treatment and diagnostics with minimal collateral damage
09/19/2013US20130245591 Injectable ibuprofen formulation
09/19/2013US20130245575 Body product and method of delivery
09/19/2013US20130245538 Control of Blood Vessel Physiology To Treat Skin Disorders
09/19/2013US20130245357 Magnetic Nanoparticle Formulations, Methods for Making Such Formulations, and Methods for their Use
09/19/2013US20130245355 3-hetaryl-substituted pyrrolo[2,3 b]pyridine derivatives as pdk1 inhibitors
09/19/2013US20130245275 Phenyl diamides and a pharmaceutical preparation comprising phenyl diamides
09/19/2013US20130245154 Controlled release dosage forms
09/19/2013US20130245128 Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
09/19/2013US20130245126 Geranylgeranylacetone formulations and retinal delivery thereof
09/19/2013US20130245124 Preservative free bimatoprost solutions
09/19/2013US20130245122 Diclofenac formulations and methods of use
09/19/2013US20130245121 Increasing glutathione levels for therapy
09/19/2013US20130245120 Injectable ibuprofen formulation
09/19/2013US20130245119 Therapeutic or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelium disorders
09/19/2013US20130245117 Novel use of capsiate or dihydrocapsidate
09/19/2013US20130245116 Compositions and methods for the disruption of mycobacterium biofilm
09/19/2013US20130245115 Pharmaceutical composition and dosage form comprising dronedarone, and preparation method thereof
09/19/2013US20130245114 Composition for treating influenza a (h1n1) virus and a preparation method therefor
09/19/2013US20130245113 Use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
09/19/2013US20130245112 Antimicrobial and antiinflammatory composition
09/19/2013US20130245111 Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
09/19/2013US20130245110 Use for cannabinoids
09/19/2013US20130245107 Dlin-mc3-dma lipid nanoparticle delivery of modified polynucleotides
09/19/2013US20130245102 Novel dna templates for small rna production in mammalian cells
09/19/2013US20130245097 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
09/19/2013US20130245096 COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA
09/19/2013US20130245093 Methods targeting mir-33 micrornas for regulating lipid metabolism
09/19/2013US20130245089 Method for administration
09/19/2013US20130245088 Ketorolac compositions for corneal wound healing
09/19/2013US20130245083 Methods of treatment with bioavailable compositions of metaxalone comprising nonvolatile liquids
09/19/2013US20130245082 Bioavailable compositions of metaxolone comprising nonvolatile liquids and processes for producing the same
09/19/2013US20130245081 Compositions and Methods for Treating Amyotrophic Lateral Sclerosis
09/19/2013US20130245080 Benzothiazolone compound
09/19/2013US20130245078 Salt compound
09/19/2013US20130245075 Melanogenesis inhibition-methods and compositions thereof
09/19/2013US20130245074 Novel compound and medical use thereof
09/19/2013US20130245073 Gel containing pirfenidone
1 ... 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 ... 7860